| Solomon Ezembakwe, | |
|
103 Oakwood Ct, New Castle, DE 19720-1383 | |
| (302) 345-1682 | |
| Not Available |
| Full Name | Solomon Ezembakwe |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 103 Oakwood Ct, New Castle, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033714738 | NPI | - | NPPES |
| A1-0003798 | Other | DE | DELAWARE BOARD OF PHARMACY |
| A1-0003798 | Other | DE | PHARMACIST |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | A1-0003798 (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Solomon Ezembakwe, 103 Oakwood Ct, New Castle, DE 19720-1383 Ph: (302) 345-1682 | Solomon Ezembakwe, 103 Oakwood Ct, New Castle, DE 19720-1383 Ph: (302) 345-1682 |
News Archive
Business analysts view the expansion as "several hundreds of billions of dollars" worth of opportunity for Medicaid health plans. Meanwhile, news organizations track the continuing debate in Kentucky, Florida, New Hampshire and Texas about whether to participate in the expansion.
In a paper recently published in the European Journal of Cancer, EORTC researchers identified health related quality of life (HRQOL) components that should be considered as most relevant for achieving optimal care for older cancer patients.
Nearly 13 percent of workers with employer-sponsored health plans who worked in firms with 10 or fewer employees had premiums of $7,200 or more a year for single-coverage plans in 2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. This amount is much higher than the $4,704 average, national premium for employer-sponsored single-coverage health plans in 2008.
AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.
Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans
› Verified 1 days ago
Nguyet Anh Le, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2034 New Castle Ave, New Castle, DE 19720 Phone: 302-658-9824 | |
Ranjita Potula, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2034 New Castle Ave, New Castle, DE 19720 Phone: 302-658-9824 | |
Mr. Garry Alan Johnson Jr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 119 W Harvest Dr, New Castle, DE 19720 Phone: 302-832-0222 | |
Mr. Murali Gouru, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 740 Ferry Cut-off, New Castle, DE 19720 Phone: 302-326-4630 | |
Mrs. Radhika Kirankumar Patel, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1413 N Dupont Hwy, New Castle, DE 19720 Phone: 302-328-8237 | |
Ms. Neelima Koduru, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 232 New Castle Ave, New Castle, DE 19720 Phone: 302-384-6925 |